India's vaccine productivity will serve needs of all: PM to S Africa Prez

The two leaders also discussed possibilities of collaboration between India and South Africa in various international fora, to facilitate access and affordability of vaccines and medicines

PM Narendra Modi
PM Narendra Modi
Press Trust of India New Delhi
2 min read Last Updated : Feb 04 2021 | 10:44 PM IST

Prime Minister Narendra Modi on Thursday told South African President Cyril Ramaphosa that India's considerable productive capacity for pharmaceuticals and vaccines would continue to serve the needs of all countries, including those in Africa.

Modi and Ramaphosa, during a telephonic conversation, discussed the continuing challenges posed by the COVID-19 pandemic, and in this context the vaccination campaigns being undertaken in their respective countries, a Prime Minister's Office (PMO) statement said.

"Spoke to President @CyrilRamaphosa about the measures India and South Africa are taking to fight the COVID-19 pandemic domestically and internationally. India's capacity to produce medicines and vaccines is supporting the efforts of many nations, including our friends in Africa," Modi said in a tweet.

The PMO also said in its statement that the prime minister reiterated to the South African president that India's considerable productive capacity for pharmaceuticals and vaccines would continue to serve the needs of all countries, including those in Africa.

The two leaders also discussed possibilities of collaboration between India and South Africa in various international fora, to facilitate access and affordability of vaccines and medicines.

Modi and Ramphosa agreed that officials of both countries would remain in touch over the coming days to exchange experiences and explore potential for collaborative efforts against the pandemic, according to the PMO.

Earlier this week, made-in-India vaccines reached South Africa in an aircraft and President Ramaphosa received the consignment of doses.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus VaccineNarendra Modi

First Published: Feb 04 2021 | 10:41 PM IST

Next Story